Clinical trial
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
NCT00127634 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00127634 |
|---|---|
| Title | Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes |
| Official title | A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Alkermes, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine |
| Enrollment | 385 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Aug 8, 2005 |
| Last update posted | Mar 9, 2018 |
| Countries | Belgium, Canada, Croatia, Hungary, India, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: